Six Months of Parathyroid Hormone (1–84) Administered ConcurrentlyVersusSequentially with Monthly Ibandronate Over Two Years: The PTH and Ibandronate Combination Study (PICS) Randomized Trial
نویسندگان
چکیده
منابع مشابه
Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis.
OBJECTIVE Corticosteroids are widely prescribed, although treatment-related side-effects are common. Of these adverse events (AEs), osteoporosis is considered the most serious. Currently, oral bisphosphonates are the standard treatment for corticosteroid-induced osteoporosis (CIO). However, intermittent intravenous (i.v.) therapy may have advantages, including lack of gastrointestinal AEs, impr...
متن کاملa case study of the two translators of the holy quran: tahereh saffarzadeh and laleh bakhtiar
بطورکلی، کتاب های مقدسی همچون قران کریم را خوانندگان میتوان مطابق با پیش زمینه های مختلفی که درند درک کنند. محقق تلاش کرده نقش پیش زمینه اجتماعی-فرهنگی را روی ایدئولوژی های مترجمین زن و در نتیجه تاثیراتش را روی خواندن و ترجمه آیات قرآن کریم بررسی کند و ببیند که آیا تفاوت های واژگانی عمده ای میان این مترجمین وجود دارد یا نه. به این منظور، ترجمه 24 آیه از آیات قرآن کریم مورد بررسی مقایسه ای قرار ...
15 صفحه اولEfficacy of a Once-Monthly Pill Containing Ibandronate and Cholecalciferol on the Levels of 25-Hydroxyvitamin D and Bone Markers in Postmenopausal Women with Osteoporosis
BACKGROUND The present study evaluated the efficacy of a combination of ibandronate and cholecalciferol on the restoration of the levels of 25-hydroxyvitamin D (25[OH]D) and various bone markers in postmenopausal women with osteoporosis. METHODS This was a randomized, double-blind, active-controlled, prospective 16-week clinical trial conducted in 20 different hospitals. A total of 201 postme...
متن کاملMonthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study.
CONTEXT Ibandronate, a potent, nitrogen-containing bisphosphonate developed for intermittent administration in postmenopausal osteoporosis, aims to overcome current adherence issues with daily and weekly oral bisphosphonates through once-monthly oral dosing. OBJECTIVE The purpose of this study was to investigate the safety, pharmacodynamics, and pharmacokinetics of once-monthly oral ibandrona...
متن کاملRenal safety of ibandronate.
Despite their efficacy in treating complications associated with metastatic bone disease, there are concerns about the potential nephrotoxicity of certain i.v. bisphosphonates for the long-term management of cancer patients. Clinical data suggest, however, that i.v. ibandronate (Bondronat); F. Hoffman-La Roche Ltd., Basel, Switzerland, http://www.roche.com), unlike other bisphosphonates, has a ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Journal of Clinical Endocrinology & Metabolism
سال: 2012
ISSN: 0021-972X,1945-7197
DOI: 10.1210/jc.2012-1844